Crispr Therapeutics AG (NASDAQ:CRSP) was the target of some unusual options trading activity on Thursday. Stock traders acquired 1,168 put options on the company. This represents an increase of 1,986% compared to the average daily volume of 56 put options.

A number of analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub raised shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. SunTrust Banks raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $22.75 price objective (down from $39.00) on shares of Crispr Therapeutics in a report on Wednesday, January 10th. Finally, Oppenheimer reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $22.81.

Crispr Therapeutics (NASDAQ:CRSP) traded up $4.94 during trading on Monday, reaching $44.39. 1,021,197 shares of the company’s stock traded hands, compared to its average volume of 1,071,188. The company has a market capitalization of $1,970.00 and a P/E ratio of -138.72. Crispr Therapeutics has a 1-year low of $11.63 and a 1-year high of $44.65.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The firm had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. During the same quarter in the previous year, the firm posted ($2.77) EPS. Crispr Therapeutics’s revenue was up 54.2% compared to the same quarter last year. equities research analysts forecast that Crispr Therapeutics will post -2.42 EPS for the current year.

In other news, insider Tyler Dylan-Hyde sold 15,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $18.90, for a total transaction of $283,500.00. Following the completion of the transaction, the insider now directly owns 130,204 shares in the company, valued at approximately $2,460,855.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $18.98, for a total transaction of $21,114,225.08. The disclosure for this sale can be found here. Insiders sold a total of 2,234,504 shares of company stock valued at $44,388,553 over the last quarter. 39.98% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. purchased a new position in shares of Crispr Therapeutics in the third quarter valued at about $536,000. Hershey Trust Co. purchased a new position in shares of Crispr Therapeutics during the third quarter valued at about $768,000. Tiff Advisory Services Inc. purchased a new position in shares of Crispr Therapeutics during the third quarter valued at about $505,000. Allianz Asset Management GmbH purchased a new position in shares of Crispr Therapeutics during the third quarter valued at about $2,384,000. Finally, Granahan Investment Management Inc. MA increased its position in shares of Crispr Therapeutics by 51.7% during the third quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after buying an additional 89,839 shares during the period. Hedge funds and other institutional investors own 21.89% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by Marea Informative and is the sole property of of Marea Informative. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.mareainformativa.com/crispr-therapeutics-sees-unusually-large-options-volume-crsp-updated-updated-updated/125364/.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.